Maria Cho
 | The topic of this article may not meet Wikipedia's notability guideline for biographies. (November 2024) |
Maria Cho is the CEO of Triplebar, a company that focuses on bioengineering solutions for food and healthcare.[1][2][3][4][5]
Education
[edit]She holds a Bachelor of Science in Chemistry from the University of Florida and a Master of Science in Biomedical Chemistry from Thomas Jefferson University.[6][7]
Career
[edit]She began her career in the laboratory, focusing on neurodegenerative disease research at Thomas Jefferson University.[8][1]
She has a background in scientific research and has held roles at WuXi AppTec, Phyla and Fujifilm Diosynth Biotechnologies.[9][7][6][10] As Co-Founder and COO of Phi Therapeutics, she led the development of a probiotic skincare line.[5][7]
She is the CEO of Triplebar, a company that focuses on developing sustainable solutions for food and healthcare.[2][3][1]
References
[edit]- ^ a b c "Maria Cho - Chief Executive Officer at Triplebar". THE ORG. Retrieved 2024-11-13.
- ^ a b "Our Leadership". Triplebar. Retrieved 2024-11-13.
- ^ a b Watson, Elaine (2023-10-30). "Triplebar raises $20m to expand bioproduct design engine 'running evolution at hyper-speed'". AgFunderNews. Retrieved 2024-11-13.
- ^ Cho, Maria. "Maria Cho - Author Biography". Entrepreneur. Retrieved 2024-11-13.
- ^ a b Redactie, Door (2024-04-01). "The Top 7 Future Tech Power Women of 2024". Mashable Benelux (in Dutch). Retrieved 2024-11-13.
- ^ a b "World Congress 2021". Charles River. Retrieved 2024-11-13.
- ^ a b c "Maria Cho | Advanced Therapies". Advanced Therapies Congress & Expo 2021. 2021-05-24. Retrieved 2024-11-13.
- ^ White, Tom. "Maria Cho, A Diversity Leader And CEO Of A Company Vying For Global Food Security And Treatments Against Diseases Of The Future". Benzinga. Retrieved 2024-11-13.
- ^ "Meet the Phyla Founding Team". Phyla Skincare. Retrieved 2024-11-13.
- ^ "A Frost & Sullivan Perspective on Commercilization Strategies in Global Biosimilars Industry" (PDF). 3m.com.